Abstract
Background and Aim
The prevalence of metabolic syndrome (MS) increased in recent years in both adolescents and children groups. The aim of the study is evaluating the relationship between insulin and uric acid (UA) level in MS in adolescents
Materials and Methods
we studied 120 adolescence aged 10 to 19 in two groups: control group without metabolic syndrome and case group with metabolic syndrome. The Criteria of ATP III was considered as a diagnosis factor for metabolic syndrome.
Discussion
Various studies have been conducted in various populations to evaluate the relationship between UA level and MS in adolescents. Abdominal obesity, low HDL, hypertriglyceridemia and hypertension are associated with high UA level. In their analysis, the MS OR in UA level⩽4.9, 4.9-5.8 and ⩾5.8 mg/dl was 1, 2.53 and 9.03, respectively, which were higher than our findings in current study. Hyperinsulinemia caused by insulin resistance is one of the complications associated with MS, which puts individuals at risk of diabetes and cardiovascular events.
Results
Uric acid level in the Case group was significantly higher than the control group (p = 0.0001, 43.8±1.4 vs. 4.1±1 mg/dl, respectively). Insulin level was significantly higher in the case group in compare to the control group (p = 0.008, 9.8± 5.3 vs. 12.2±6 μU/ml, respectively).
Conclusion
The findings of this case-control study showed that adolescents with metabolic syndrome have a higher uric acid and insulin level in compare to normal subjects. We hypothesis that increase in serum insulin and uric acid level can be a risk factor in the development of metabolic syndrome.
Similar content being viewed by others
References
Anderson J L, May H T, Horne B D, Bair T L, Hall N L, Carlquist J F, Lappé D L, Muhlestein J B, and the Intermountain Heart Collaborative (IHC) Study Group (2010). Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol, 106(7): 963–968
Balkau B, Charles M A, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin J S, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B, and the European Group For The Study Of Insulin Resistance (EGIR) (2002). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab, 28 (5): 364–376
Cardoso A S, Gonzaga N C, Medeiros C C, Carvalho D F (2013). Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents. J Pediatr (Rio J), 89(4): 412–418
Chen J H, Chuang S Y, Chen H J, Yeh WT, Pan WH (2009). Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum, 61(2): 225–232
Currie G, Delles C (2013). Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis, 7: 13–24
de Ferranti S D, Gauvreau K, Ludwig D S, Neufeld E J, Newburger J W, Rifai N (2004). Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation, 110(16): 2494–2497
DeBoer M D, Dong L, Gurka M J (2011). Racial/ethnic and sex differences in the ability of metabolic syndrome criteria to predict elevations in fasting insulin levels in adolescents. The Journal of pediatrics. 159(6):975–81. e3
Ford E S, Li C, Cook S, Choi H K (2007). Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation, 115(19): 2526–2532
Haffner S M (2006). The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol, 97(2 2A): 3A–11A
Han T S, Lean M E (2016). A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis, 5: 2048004016633371
Hanley A J, Karter A J, Williams K, Festa A, D’Agostino R B Jr, Wagenknecht L E, Haffner S M (2005). Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation, 112(24): 3713–3721
Haybar H, Jalali M, Zayeri Z (2018). What genetic tell us about cardiovascular disease in diabetic patients. Cardiovasc Hematol Disord Drug Targets, 18(2): 147–152
Haybar H, Zayeri Z D (2017). The value of using polymorphisms in antiplatelet therapy. Frontiers in Biology., 12(5): 349–356
Kassi E, Pervanidou P, Kaltsas G, Chrousos G (2011). Metabolic syndrome: definitions and controversies. BMC Med, 9(1): 48
Kaur J (2014). A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014: 943162
Kelly C T, Mansoor J, Dohm G L, Chapman W H 3rd, Pender J R 4th, Pories W J (2014). Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery, 156(2): 405–411
Li C, Hsieh M C, Chang S J (2013). Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol, 25(2): 210–216
Li Q, Zhou Y, Dong K, Wang A, Yang X, Zhang C, Zhu Y, Wu S, Zhao X (2015). The association between serum uric acid levels and the prevalence of vulnerable atherosclerotic carotid plaque: a crosssectional study. Sci Rep, 5(1): 10003
Li X, Song P, Li J, Wang P, Li G (2015). Relationship between hyperuricemia and dietary risk factors in Chinese adults: a crosssectional study. Rheumatol Int, 35(12): 2079–2089
Lteif A A, Han K, Mather K J (2005). Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation, 112(1): 32–38
MacPherson M, de Groh M, Loukine L, Prud’homme D, Dubois L (2016). Prevalence of metabolic syndrome and its risk factors in Canadian children and adolescents: Canadian Health Measures Survey Cycle 1 (2007–2009) and Cycle 2 (2009–2011). Health Promot Chronic Dis Prev Can, 36(2):32–40
Nejatinamini S, Ataie-Jafari A, Qorbani M, Nikoohemat S, Kelishadi R, Asayesh H, Hosseini S (2015). Association between serum uric acid level and metabolic syndrome components. J Diabetes Metab Disord, 14(1): 70
Orchard T J, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, and the Diabetes Prevention Program Research Group (2005). The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med, 142(8): 611–619
Perez-Ruiz F, Becker M (2015). Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin, 31 Suppl 2: 9–14
Ritchie S A, Connell J M (2007). The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis, 17(4): 319–326
Rutter M K, Meigs J B, Sullivan L M, D’Agostino R B Sr, Wilson P W (2005). Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes, 54(11): 3252–3257
Shahbazian H, Absalan A, Jalali MT, Mastipour F, Kaydani G A, Zayeri Z D (2018). Comparison of zinc, copper, selenium, magnesium, aluminium and lead blood concentrations in end-stage renal disease patients and healthy volunteers in Ahvaz, southwest of Iran. Russian Open Medical Journal, 7(1):Article CID e0105
Sun H L, Pei D, Lue K H, Chen Y L (2015). Uric acid levels can predict metabolic syndrome and hypertension in adolescents: a 10-year longitudinal study. PLoS One, 10(11): e0143786
Sung K C C, Seo M H H, Rhee E J J, Wilson A M (2011). Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol, 10(1): 108
Acknowledgment
This study was supported by Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rashidi, H., Shahbazian, H., Nokhostin, F. et al. The comparison of insulin and uric acid levels in adolescents with and without metabolic syndrome. Front. Biol. 13, 452–457 (2018). https://doi.org/10.1007/s11515-018-1515-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11515-018-1515-1